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CASE REPORT
We report the case of a 53-year-old Japanese woman with no 
smoking history, who suffered general fatigue for 2 months. 
Radiological screening showed a right lower lung (RLL) mass 
(Fig. 1), and she was diagnosed with stage IV lung adenocar-
cinoma (cT4N3M1b) with pulmonary, bone, and brain metas-
tases. Fluorescence in situ hybridization revealed anaplastic 
lymphoma kinase (ALK) gene rearrangement. Crizotinib 
(ALK inhibitor, 250 mg twice daily) was initiated as first-line 
chemotherapy in May 2012. Symptoms and chest radiological 
findings improved until day 10, when she developed a non-
productive cough. Despite levofloxacine treatment, the dry 
cough and dyspnea progressively worsened. On day 14, chest 
computed tomography revealed partial remission of the RLL 
tumor, although new bilateral ground-glass opacities were 
noted (Fig. 2A). Because of hypoxemia (oxygen saturation 
in room air was 90%), further diagnostic studies could not be 
performed. No pulmonary pathogens were identified and we 
considered the lesions to be consistent with crizotinib-induced 
interstitial lung disease (ILD). Crizotinib was immediately 
discontinued, and intravenous high-dosage methylpredniso-
lone (1000 mg daily for 3 days) was initiated, which improved 
her symptoms and lung shadow, although the RLL mass grew 
larger (Fig. 2B). As the disease progressed, we tried various 
regimens of conventional chemotherapy, such as carboplatin/
pemetrexed, S-1, and docetaxel; all of which were ineffective. 
Her respiratory distress worsened, and she required supplemen-
tal nasal oxygen (2.0 liter/minutes). The patient and her family 
expressed their wish to retry the crizotinib treatment, even after 
the risk of recurrent ILD was explained. Crizotinib treatment 
was recommenced in January 2013 (250 mg twice daily), with 
intravenous dexamethasone (6.6 mg daily). The general condi-
tion of the patient gradually stabilized, and oxygen supplemen-
tation became unnecessary. No pulmonary toxicity recurred, 
and partial tumor remission was achieved (Fig. 3). The steroid 
dosage was tapered gradually on a weekly basis, until it was 
2 mg daily. She was discharged on day 20, and at 2 months 
there was neither disease progression nor recurrence of ILD.
DISCUSSION
Echinoderm microtubule-associated protein-like 4 (EML4)-
ALK rearrangement occurs in approximately 5% of patients 
with non–small-cell lung carcinoma,1 especially those with ade-
nocarcinoma.2 Crizotinib is recommended as first-line therapy 
for patients with EML4-ALK–mutant lung cancer. Although 
its adverse effects are relatively mild, ILD is an infrequent, but 
life-threatening pulmonary toxicity.3 With crizotinib-induced 
ILD, permanent drug withdrawal is inevitable, although there 
is currently no effective alternative therapy. Drug-induced 
ILD has also been reported with other tyrosine kinase inhibi-
tors (TKIs), such as epidermal growth factor receptor–TKIs 
(EGFR-TKIs).4 Recent reports describe the safety and efficacy 
of EGFR-TKI retreatment, even after EGFR-TKI-induced 
ILD, and imply the need for steroid pretreatment to reduce ILD 
recurrence.5 In case of crizotinib, there have not been any pre-
vious reports on the retreatment after crizotinib-induced ILD. 
Thus, dexamethasone was used in our case after the example 
of EGFR-TKI retreatment. In addition, a relatively long inpa-
tient follow-up may be reasonable, as most cases of crizotinib-
induced ILD are reported in the first 3 weeks.
In conclusion, this is, to our knowledge, the first report of a 
successful crizotinib retreatment after crizotinib-induced ILD. In 
selected patients with EML4-ALK–mutant lung cancer, crizo-
tinib retreatment might be considered with careful monitoring.
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FIGURE 3.  Chest computed tomography scan 
before and after crizotinib retreatment. A, Before 
treatment with crizotinib, the scan showed the right 
lower mass and bilateral lung metastases. B, Two 
months after the initiation of crizotinib, the scan 
showed a partial remission of the right lower lung 
tumor without recurrence of interstitial lung disease.
FIGURE 2.  Crizotinib-induced interstitial lung 
disease. A, A chest CT scan performed 14 days after 
initiation of crizotinib treatment showing a decrease 
in size of the main tumor, but visible bilateral 
ground-glass opacities. B, CT scan 5 days after ces-
sation of crizotinib and initiation of corticosteroid, 
showed improvement of air space consolidations, 
despite the right lower lobe tumor enlargement. CT, 
computed tomography.
FIGURE 1.  PET and CT of a 53-year-old woman. 
Both PET scan (A) and CT scan (B) showed a mass in 
the right lower lobe with bilateral, multiple pulmo-
nary nodules. PET, positron emission tomography; 
CT, computed tomography.
